New Treatment Option for COPD: Striverdi Respimat

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

Striverdi Respimat (olodaterol) is indicated for the long-term treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are experiencing airflow obstruction.

What is COPD?

COPD (chronic obstructive pulmonary disease) affects the airways within the lungs, making it harder to breathe, and can get worse as time goes on. There are two forms of COPD: chronic bronchitis and emphysema. Many people who smoke or use to smoke are affected by COPD; however, it can also be due to exposure to pollution, chemical fumes, or dust.

There are several types of long-term or maintenance medications available to help you breathe better and improve lung function–Striverdi is the newest maintenance inhaler option.

When was Striverdi Respimat approved?
Striverdi was approved on July 31, 2014, however, there isn’t an estimated availability date yet. Keep an eye out in the coming months for more information.

How should Striverdi Respimat be taken?
Striverdi Respimat is an oral inhalation spray that is used once-daily.

What are some side effects of Striverdi Respimat?

The most common side effects include nasopharyngitis (AKA the common cold) or other upper respiratory tract infection, urinary tract infection, dizziness, rash, diarrhea, back pain, and joint pain.

What type of medication is Striverdi Respimat and how does it work?
Striverdi Respimat is a long-acting beta2-adrenergic agonist (LABA). LABAs work by relaxing the muscle of the airways within the lungs, which leads to easier breathing.

Can you use Striverdi Respimat on an as-needed basis?

NO. This is a once-daily maintenance medication that will need to be used whether you think you need it or not.

Which other medications are indicated for the long-term treatment of COPD?

Some other long-term maintenance medications for COPD include Serevent Diskus, Arcapta, Spiriva Handihaler, Tudorza Pressair, Incruse Ellipta (also recently approved, in April 2014).

You can find more information from the FDA on Striverdi Respimat here.

Drugs featured in this story

Filed under